Liang M - Search Results

1

Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.

Shah NN, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, Dalla-Pozza L, Dennis R, Hijiya N, Locatelli F, Martin PL, Mechinaud F, Moppett J, Rheingold SR, Schmitt C, Trippett TM, Liang M, Balic K, Li X, Vainshtein I, Yao NS, Pastan I, Wayne AS. Shah NN, et al. Among authors: liang m. Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15. Pediatr Blood Cancer. 2020. PMID: 31944549 Free PMC article. Clinical Trial.

2

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, Sun W, Liang M, Yang J, Kreitman RJ, Lanasa MC, Pastan I. Wayne AS, et al. Among authors: liang m. Blood. 2017 Oct 5;130(14):1620-1627. doi: 10.1182/blood-2017-02-749101. Epub 2017 Aug 9. Blood. 2017. PMID: 28983018 Free PMC article. Clinical Trial.

3

Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia.

Kuruvilla D, Chia YL, Balic K, Yao NS, Kreitman RJ, Pastan I, Li X, Standifer N, Liang M, Tseng CM, Faggioni R, Roskos L. Kuruvilla D, et al. Among authors: liang m. Br J Clin Pharmacol. 2020 Jul;86(7):1367-1376. doi: 10.1111/bcp.14250. Epub 2020 Mar 16. Br J Clin Pharmacol. 2020. PMID: 32077130 Free PMC article.

4

A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains.

Vainshtein I, Sun B, Roskos LK, Liang M. Vainshtein I, et al. Among authors: liang m. J Immunol Methods. 2020 Feb;477:112688. doi: 10.1016/j.jim.2019.112688. Epub 2019 Oct 30. J Immunol Methods. 2020. PMID: 31676342

5

An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.

Schneider AK, Vainshtein I, Roskos LK, Chavez C, Sun B, Liang M. Schneider AK, et al. Among authors: liang m. J Immunol Methods. 2016 Aug;435:68-76. doi: 10.1016/j.jim.2016.05.007. Epub 2016 May 21. J Immunol Methods. 2016. PMID: 27220271

6

Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.

Wang B, Liang M, Yao Z, Vainshtein I, Lee R, Schneider A, Zusmanovich M, Jin F, O'Connor K, Donato-Weinstein B, Iciek L, Lavallee T, Roskos L. Wang B, et al. Among authors: liang m. J Pharm Sci. 2013 Jan;102(1):250-61. doi: 10.1002/jps.23343. Epub 2012 Oct 22. J Pharm Sci. 2013. PMID: 23090886

7

First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer.

Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, Liang M, He P, Marshall S, Scheuber A, Das M, Patel MR. Pegram MD, et al. Among authors: liang m. Mol Cancer Ther. 2021 Aug;20(8):1442-1453. doi: 10.1158/1535-7163.MCT-20-0014. Epub 2021 May 27. Mol Cancer Ther. 2021. PMID: 34045233 Free PMC article. Clinical Trial.

8

A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy.

Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. Liang M, et al. AAPS J. 2020 Nov 18;23(1):4. doi: 10.1208/s12248-020-00523-3. AAPS J. 2020. PMID: 33210183

9

Interference in immunoassays to support therapeutic antibody development in preclinical and clinical studies.

Schwickart M, Vainshtein I, Lee R, Schneider A, Liang M. Schwickart M, et al. Among authors: liang m. Bioanalysis. 2014;6(14):1939-51. doi: 10.4155/bio.14.127. Epub 2014 May 8. Bioanalysis. 2014. PMID: 24806787

10

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody.

Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK, Vainshtein I. Cheng J, et al. Among authors: liang m. Antibodies (Basel). 2020 Sep 18;9(3):49. doi: 10.3390/antib9030049. Antibodies (Basel). 2020. PMID: 32961882 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,025 results

Search Page